<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564079</url>
  </required_header>
  <id_info>
    <org_study_id>Exactis-01</org_study_id>
    <nct_id>NCT04564079</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network</brief_title>
  <official_title>A Multi-Centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer Within the Exactis Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exactis Innovation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exactis Innovation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic&#xD;
      Aberration results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small&#xD;
      Cell Lung Cancer Patients within the Exactis Network&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective multi-center observational study will evaluate the clinical utility of&#xD;
      returning genomic aberration results in blood and/or tissue using the Oncomine Precision&#xD;
      Assay in non-small cell lung cancer (NSCLC) patients. Up to 200 patients with stage IIIb/IV&#xD;
      NSCLC will consent to have their blood and tissue profiled on the Oncomine Precision Assay. A&#xD;
      baseline plasma sample will be collected for all patients, of which up to 100 patients will&#xD;
      have a tissue sample collected from pathology archives or planned biopsy or surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study is temporarily on hold until lack of consistency in the level of quality observed in the&#xD;
    sequencing results of patient samples is resolved.&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate the non-inferiority of the Oncomine Precision Assay vs Standard of Care</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patients for whom a genomic aberration is detected in at least one of the eight genes (ROS1, ERBB2, MET, BRAF, KRAS, RET, ALK, EGFR) using the Oncomine Precision Assay vs. study site's standard of care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical utility of returning genomic aberration results by quantifying the number of patients who received targeted therapy based on results returned from the Oncomine Precision Assay genomic aberration results in blood and/or tissue</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical utility of returning genomic aberration results by quantifying the number of patients enrolled on a clinical trial based on results returned from the Oncomine Precision Assay in blood and/or tissue</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical utility of returning genomic aberration results by measuring the turnaround time (in days) from the date of request for SOC genetic testing in tissue versus date of blood collection for the Oncomine Precision Assay to the report date</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory - Analytical validity of Oncomine Precision Assay</measure>
    <time_frame>3 years</time_frame>
    <description>Number of genomic aberrations concordant and discordant between tissue and blood using the Oncomine Precision Assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Assessment of tumor evolution using Oncomine Precision Oncology assay on sequential ctDNA samples</measure>
    <time_frame>3 years</time_frame>
    <description>Mutation, copy number variation and fusion variant types across 50 key genes will be assessed using the Oncomine Precision Assay in blood samples collected at progression from patients that received targeted therapy and compared to the baseline matched specimen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Sensitivity and specificity of mutation detection analysis of extracellular vesicles (EV) total nucleic acids</measure>
    <time_frame>3 years</time_frame>
    <description>Compare the sensitivity and specificity of mutation detection in extracellular vesicles (EV) total nucleic acids and circulating tumor total nucleic acids</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Explore the response patterns to treatment based on EV RNAs</measure>
    <time_frame>3 years</time_frame>
    <description>Small RNA extracted from plasma EV at baseline and at progression will be analyzed using RNA sequencing. Potential association between expression profiles and clinical parameters such as treatment response will be explored and candidate patterns predictive of treatment response will be tested using artificial intelligence algorithms.</description>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>NSCLC</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and/or tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NSCLC, which is i) advanced or metastatic (stage IIIb/IV), ii) non-squamous&#xD;
        histology NSCLC as confirmed by local histopathology (mixed squamous and adenocarcinoma is&#xD;
        allowed).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NSCLC, which is (i) advanced or metastatic (stage IIIb/IV), (ii) non-&#xD;
             squamous histology NSCLC as confirmed by local histopathology (mixed squamous and&#xD;
             adenocarcinoma is allowed), and has (iii) radiographically measurable disease with at&#xD;
             least one bidimensionally measurable lesion of &gt; 1 cm by CT scan&#xD;
&#xD;
          -  No prior treatment for advanced or metastatic NSCLC&#xD;
&#xD;
          -  Willing and able to provide adequate blood sample prior to starting treatment.&#xD;
&#xD;
          -  Willing to provide primary or metastatic tissue, if available.&#xD;
&#xD;
          -  Signed and dated Research Ethics Board (REB)-approved informed consent form for&#xD;
             Exactis-01 or PMT.&#xD;
&#xD;
          -  Not pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Patients who have a history of another active cancer within the past 2 years from date of&#xD;
        consent except cervical cancer in situ, basal cell carcinoma of the skin or another in situ&#xD;
        carcinoma that is considered cured by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Agulnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Dr-Georges-L.-Dumont</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.exactis.ca</url>
    <description>exactis.ca</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT02355171?term=personalize+me+treatment&amp;draw=2&amp;rank=9</url>
    <description>PMT registry</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genomic Aberrations</keyword>
  <keyword>Exactis Network</keyword>
  <keyword>Advanced or Metastatic Non-Small Cell Lung Cancer</keyword>
  <keyword>Liquid Biopsy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As in the PMT registry, data and samples will be collected, coded and stored in secure and protected installations. Information and samples provided to researchers will be double-coded so that they cannot be traced back to you. Exactis takes great care to protect participants' data and samples, to minimize security risks and the possibility of a confidentiality breach.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

